Prebiotics and Inflammatory Bowel Disease

Gastroenterology Clinics of North America

Volumn 46, Issue 4, 2017, Pages 783-795

  Rasmussen, Heather E ^a   Hamaker, Bruce R ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Crohn disease; Fiber; Inflammatory bowel disease; Prebiotics; Ulcerative colitis

Indexed keywords

PREBIOTIC AGENT;

BACTERIAL STRAIN; CHEMICAL STRUCTURE; CLINICAL OUTCOME; CROHN DISEASE; DIET THERAPY; DIETARY FIBER; DISEASE COURSE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; REVIEW; ULCERATIVE COLITIS; ADMINISTRATION AND DOSAGE; ANIMAL; MICROBIOLOGY;

ANIMALS; DIETARY FIBER; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; PREBIOTICS;

EID: 85030454053     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2017.08.004     Document Type: Review

References (41)

1. Hutkins, R.W., Krumbeck, J.A., Bindels, L.B., et al. Prebiotics: why definitions matter. Curr Opin Biotechnol 37 (2016), 1–7.
2. Gibson, G.R., Fuller, R., Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J Nutr 130:2S Suppl (2000), 391S–395S.
3. Hamaker, B.R., Tuncil, Y.E., A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota. J Mol Biol 426:23 (2014), 3838–3850.
4. Sonnenburg, E.D., Sonnenburg, J.L., Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab 20:5 (2014), 779–786.
5. Flint, H.J., Bayer, E.A., Rincon, M.T., et al. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 6:2 (2008), 121–131.
6. Van den Abbeele, P., Gerard, P., Rabot, S., et al. Arabinoxylans and inulin differentially modulate the mucosal and luminal gut microbiota and mucin-degradation in humanized rats. Environ Microbiol 13:10 (2011), 2667–2680.
7. Kappelman, M.D., Rifas-Shiman, S.L., Kleinman, K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the united states. Clin Gastroenterol Hepatol 5:12 (2007), 1424–1429.
8. Loftus, E.V. Jr., Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:6 (2004), 1504–1517.
9. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3:7 (2006), 390–407.
10. de Mattos, B.R., Garcia, M.P., Nogueira, J.B., et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm, 2015, 2015, 493012.
11. Bernstein, C.N., Shanahan, F., Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57:9 (2008), 1185–1191.
12. Sheehan, D., Shanahan, F., The gut microbiota in inflammatory bowel disease. Gastroenterol Clin North Am 46:1 (2017), 143–154.
13. Shanahan, F., Quigley, E.M., Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 146:6 (2014), 1554–1563.
14. Kostic, A.D., Xavier, R.J., Gevers, D., The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146:6 (2014), 1489–1499.
15. Quevrain, E., Maubert, M.A., Michon, C., et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65:3 (2016), 415–425.
16. Joossens, M., Huys, G., Cnockaert, M., et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60:5 (2011), 631–637.
17. Sokol, H., Seksik, P., Furet, J.P., et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15:8 (2009), 1183–1189.
18. Sokol, H., Pigneur, B., Watterlot, L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:43 (2008), 16731–16736.
19. Jansson, J., Willing, B., Lucio, M., et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One, 4(7), 2009, e6386.
20. Marchesi, J.R., Holmes, E., Khan, F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6:2 (2007), 546–551.
21. Hamer, H.M., Jonkers, D., Venema, K., et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27:2 (2008), 104–119.
22. US Department of Agriculture, Agricultural Research Service. Nutrient intakes from food: mean amounts consumed per individual, by gender and age, what we eat in America, NHANES 2013-2014. 2014. Available at: www.ars.usda.gov/ba/bhnrc/fsrg. Accessed June 1, 2017.
23. Rose, D.J., Venema, K., Keshavarzian, A., et al. Starch-entrapped microspheres show a beneficial fermentation profile and decrease in potentially harmful bacteria during in vitro fermentation in faecal microbiota obtained from patients with inflammatory bowel disease. Br J Nutr 103:10 (2010), 1514–1524.
24. Hoentjen, F., Welling, G.W., Harmsen, H.J., et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 11:11 (2005), 977–985.
25. Lara-Villoslada, F., de Haro, O., Camuesco, D., et al. Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. Eur J Nutr 45:7 (2006), 418–425.
26. Larrosa, M., Yanez-Gascon, M.J., Selma, M.V., et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 57:6 (2009), 2211–2220.
27. Cherbut, C., Michel, C., Lecannu, G., The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr 133:1 (2003), 21–27.
28. Chiba, M., Abe, T., Tsuda, H., et al. Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. World J Gastroenterol 16:20 (2010), 2484–2495.
29. James, S.L., Christophersen, C.T., Bird, A.R., et al. Abnormal fibre usage in UC in remission. Gut 64:4 (2015), 562–570.
30. Lindsay, J.O., Whelan, K., Stagg, A.J., et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55:3 (2006), 348–355.
31. Su, C., Lichtenstein, G.R., Krok, K., et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126:5 (2004), 1257–1269.
32. Benjamin, J.L., Hedin, C.R., Koutsoumpas, A., et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 60:7 (2011), 923–929.
33. De Preter, V., Joossens, M., Ballet, V., et al. Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial. Clin Transl Gastroenterol, 4, 2013, e30.
34. Casellas, F., Borruel, N., Torrejon, A., et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 25:9 (2007), 1061–1067.
35. Kanauchi, O., Mitsuyama, K., Homma, T., et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med 12:5 (2003), 701–704.
36. Kanauchi, O., Iwanaga, T., Mitsuyama, K., Germinated barley foodstuff feeding. A novel neutraceutical therapeutic strategy for ulcerative colitis. Digestion 63:Suppl 1 (2001), 60–67.
37. Hanai, H., Kanauchi, O., Mitsuyama, K., et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 13:5 (2004), 643–647.
38. Fernandez-Banares, F., Hinojosa, J., Sanchez-Lombrana, J.L., et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 94:2 (1999), 427–433.
39. Fujimori, S., Gudis, K., Mitsui, K., et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 25:5 (2009), 520–525.
40. Furrie, E., Macfarlane, S., Kennedy, A., et al. Synbiotic therapy (Bifidobacterium longum/synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54:2 (2005), 242–249.
41. Ishikawa, H., Matsumoto, S., Ohashi, Y., et al. Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 84:2 (2011), 128–133.